The pharmacotherapeutic management of nail unit and acral melanomas

References

• Reed R. New concepts in surgical pathology of skin. New York: Wiley. 1976:89–90.
   Google Scholar
• Goydos JS, Shoen SL. Acral lentiginous melanoma. Cancer Treat Res. 2016;167:321–329.
   PubMedGoogle Scholar
• Kibbi N, Kluger H, Choi JN. Melanoma: clinical presentations. Cancer Treat Res. 2016;167:107–129.
   PubMedGoogle Scholar
• Bradford PT, Goldstein AM, McMaster ML, et al. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145(4):427–434.
   PubMedGoogle Scholar
• Markovic SN, Erickson LA, Rao RD, et al., editors. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. ; 2007;83(3): 364–80 .
   Google Scholar
• American Cancer Society. Cancer facts & figures for African Americans 2019‐2021. Atlanta, 2019.
   Google Scholar
• Marchetti MA, Adamson AS, Halpern AC. Melanoma and racial health disparities in black individuals—facts, fallacies, and fixes. JAMA Dermatol. 2021;157(9):1031–1032.
   PubMedGoogle Scholar
• Piliang MP. Acral lentiginous melanoma. Surg Pathol Clin. 2009;2(3):535–541.
   PubMedGoogle Scholar
• Zell JA, Cinar P, Mobasher M, et al. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008;26(1):66–675.
   PubMedGoogle Scholar
• Madankumar R, Gumaste PV, Martires K, et al. Acral melanocytic lesions in the United States: Prevalence, awareness, and dermoscopic patterns in skin-of-color and non-hispanic white patients. J Am Acad Dermatol. 2016;74(4):724–730. e1.
   PubMed Web of Science ®Google Scholar
• Tuma B, Yamada S, Atallah ÁN, et al. Dermoscopy of black skin: a cross-sectional study of clinical and dermoscopic features of melanocytic lesions in individuals with type V/VI skin compared to those with type I/II skin. J Am Acad Dermatol. 2015;73(1):114–119.
   PubMedGoogle Scholar
• Hudson D, Krige J. Melanoma in black South Africans. J Am Coll Surg. 1995;180(1):65–71.
   PubMed Web of Science ®Google Scholar
• Chang JW-C, Yeh K-Y, Wang C-H, et al. Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res. 2004;14(6):537–541.
   PubMedGoogle Scholar
• Darmawan CC, Jo G, Montenegro SE, et al. Early detection of acral melanoma: a review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019;81(3):805–812.
   PubMed Web of Science ®Google Scholar
• Phan A, Touzet S, Dalle S, et al. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol. 2006;155(3):561–569.
   PubMedGoogle Scholar
• Cho KK, Cust AE, Foo YM, et al., Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis. Melanoma Res. 2021;31(5):482–486.
   PubMedGoogle Scholar
• Teramoto Y, Keim U, Gesierich A, et al. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol. 2018;178(2):443–451.
   PubMed Web of Science ®Google Scholar
• Metzger S, Ellwanger U, Stroebel W, et al. Extent and consequences of physician delay in the diagnosis of acral melanoma. Melanoma Res. 1998;8(2):181–186.
   PubMed Web of Science ®Google Scholar
• Kuchelmeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol. 2000;143(2):275–280.
   PubMed Web of Science ®Google Scholar
• Nagore E, Pereda C, Botella-Estrada R, et al. Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. Cancer Causes Control. 2009;20(1):115–119.
   PubMedGoogle Scholar
• Jung HJ, Kweon -S-S, Lee J-B, et al. A clinicopathologic analysis of 177 acral melanomas in Koreans: relevance of spreading pattern and physical stress. JAMA Dermatol. 2013;149(11):1281–1288.
   PubMedGoogle Scholar
• Minagawa A, Omodaka T, Okuyama R. Melanomas and mechanical stress points on the plantar surface of the foot. N Engl J Med. 2016;374(24):2404–2406.
   PubMedGoogle Scholar
• Sheen Y-S, Liao Y-H, Lin M-H, et al. A clinicopathological analysis of 153 acral melanomas and the relevance of mechanical stress. Sci Rep. 2017;7(1):1–6.
   PubMedGoogle Scholar
• Criscito MC, Stein JA. Improving the diagnosis and treatment of acral melanocytic lesions. Melanoma Manage. 2017;4(2):113–123.
   PubMedGoogle Scholar
• Torres-Cabala CA, Wang W-L, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 2009;22(11):1446–1456.
   PubMedGoogle Scholar
• Zebary A, Omholt K, Vassilaki I, et al. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci. 2013;72(3):284–289.
   PubMed Web of Science ®Google Scholar
• Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(21):6821–6828.
   PubMed Web of Science ®Google Scholar
• Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–180.
   PubMed Web of Science ®Google Scholar
• Ashida A, Uhara H, Kiniwa Y, et al. Assessment of BRAF and KIT mutations in Japanese melanoma patients. J Dermatol Sci. 2012;66(3):240–242.
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–2147.
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Strickland N, Nijhawan RI, et al. Nail unit melanoma in situ treated with mohs micrographic surgery. Dermatol Surg. 2021;47(1):98–103.
   PubMedGoogle Scholar
• Ko D, Oromendia C, Scher R, et al., Retrospective single-center study evaluating clinical and dermoscopic features of longitudinal melanonychia, ABCDEF criteria, and risk of malignancy. J Am Acad Dermatol. 2019;80(5):1272–1283.
   PubMedGoogle Scholar
• André J, Lateur N. Pigmented nail disorders. Dermatol Clin. 2006;24(3):329–339.
   PubMed Web of Science ®Google Scholar
• Baran R, Kechijian P. Longitudinal melanonychia (melanonychia striata): diagnosis and management. J Am Acad Dermatol. 1989;21(6):1165–1175.
   PubMed Web of Science ®Google Scholar
• Thai KE, Young R, Sinclair RD. Continuing medical education review nail apparatus melanoma. Australas J Dermatol. 2001;42(2):71–83.
   PubMedGoogle Scholar
• Quinn MJ, Thompson JE, Crotty K, et al. Subungual melanoma of the hand. J Hand Surg Am. 1996;21(3):506–511.
   PubMedGoogle Scholar
• Haneke E. Ungual melanoma–controversies in diagnosis and treatment. Dermatol Ther. 2012;25(6):510–524.
   PubMedGoogle Scholar
• Nevares-Pomales OW, Sarriera-Lazaro CJ, Barrera-Llaurador J, et al. Pigmented lesions of the nail unit. Am J Dermatopathol. 2018;40(11):793–804.
   PubMedGoogle Scholar
• Tosti A, Piraccini BM, Cagalli A, et al. in situ melanoma of the nail unit in children: report of two cases in fair-skinned caucasian children. Pediatr Dermatol. 2012;29(1):79–83.
   PubMedGoogle Scholar
• Iorizzo M, Tosti A, Di Chiacchio N, et al. Nail melanoma in children: differential diagnosis and management. Dermatol Surg. 2008;34(7):974–978.
   PubMedGoogle Scholar
• Di Chiacchio N, Hirata SH, Enokihara MY, et al. Dermatologists’ accuracy in early diagnosis of melanoma of the nail matrix. Arch Dermatol. 2010;146(4):382–387.
   PubMedGoogle Scholar
• Tan K-B, Moncrieff M, Thompson JF, et al. Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting. Am J Surg Pathol. 2007;31(12):1902–1912.
   PubMed Web of Science ®Google Scholar
• Banfield C, Dawber R. Nail melanoma: a review of the literature with recommendations to improve patient management. Br J Dermatol. 1999;141(4):628–632.
   PubMedGoogle Scholar
• High WA, Quirey RA, Guillén DR, et al. Presentation, histopathologic findings, and clinical outcomes in 7 cases of melanoma in situ of the nail unit. Arch Dermatol. 2004;140(9):1102–1106.
   PubMedGoogle Scholar
• Levit EK, Kagen MH, Scher RK, et al. The ABC rule for clinical detection of subungual melanoma. J Am Acad Dermatol. 2000;42(2):269–274.
   PubMedGoogle Scholar
• Jellinek NJ, Lipner SR. Longitudinal erythronychia: retrospective single-center study evaluating differential diagnosis and the likelihood of malignancy. Dermatol Surg. 2016;42(3):310–319.
   PubMedGoogle Scholar
• Shukla V, Hughes L. Differential diagnosis of subungual melanoma from a surgical point of view. Journal of British Surgery. 1989;76(11):1156–1160.
   PubMedGoogle Scholar
• Bello DM, Chou JF, Panageas KS, et al. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol. 2013;20(11):3618–3625.
   PubMed Web of Science ®Google Scholar
• Gumaste PV, Fleming NH, Silva I, et al. Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines? J National Compr Cancer Network. 2014;12(12):1706–1712.
   PubMedGoogle Scholar
• Korn EL, Liu P-Y, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J clin oncol. 2008;26(4):527–534.
   PubMed Web of Science ®Google Scholar
• Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf. 2017;16(12):1347–1357.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546.
   PubMed Web of Science ®Google Scholar
• Ribas A, Lawrence D, Atkinson V, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019;25(6):936–940.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–730.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J clin oncol. 2021;39(15_suppl):9506–9506.
   Google Scholar
• Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588(2):368–376.
   PubMed Web of Science ®Google Scholar
• Baxter AG, Hodgkin PD. Activation rules: the two-signal theories of immune activation. Nat Rev Immunol. 2002;2(6):439–446.
   PubMed Web of Science ®Google Scholar
• Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Bradshaw J, Greene J, et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996;4(6):535–543.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32–42.
   PubMed Web of Science ®Google Scholar
• Sandin LC, Eriksson F, Ellmark P, et al. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology. 2014;3(1):e27614.
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695–1710.
   PubMed Web of Science ®Google Scholar
• Wen X, Ding Y, Li J, et al. The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series. Cancer Immunol Immunother. 2017;66(9):1153–1162.
   PubMedGoogle Scholar
• Johnson DB, Peng C, Abramson RG, et al. Clinical activity of ipilimumab in acral melanoma: a retrospective review. Oncologist. 2015;20(6):648.
   PubMed Web of Science ®Google Scholar
• Häfliger EM, Ramelyte E, Mangana J, et al. Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. Melanoma Res. 2018;28(5):442–450.
   PubMedGoogle Scholar
• Shaw H, Larkin J, Corrie P, et al. Ipilimumab for advanced melanoma in an expanded access programme (EAP): ocular, mucosal and acral subtype UK experience. Ann Oncol. 2012;23:ix374.
   Google Scholar
• Zaremba A, Murali R, Jansen P, et al. Clinical and genetic analysis of melanomas arising in acral sites. Eur J Cancer. 2019;119:66–76.
   PubMedGoogle Scholar
• Jung M, Lee J, Kim TM, et al. Ipilimumab real-world efficacy and safety in Korean melanoma patients from the Korean named-patient program cohort. Cancer Res Treat. 2017;49(1):44.
   PubMedGoogle Scholar
• Yamazaki N, Kiyohara Y, Uhara H, et al. Real‐world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: a postmarketing surveillance. J Dermatol. 2020;47(8):834–848.
   PubMed Web of Science ®Google Scholar
• Ribas A. Semin Oncol. 2010;37(5): 450–4.
   PubMed Web of Science ®Google Scholar
• Eroglu Z, Kim DW, Wang X, et al. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015;51(17):2689–2697.
   PubMedGoogle Scholar
• Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J clin oncol. 2009;27(7):1075–1081.
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J clin oncol. 2013;31(5):616.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677–704.
   PubMed Web of Science ®Google Scholar
• Raedler LA. Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma. Am Health Drug Benefits. 2015;8(Spec Feature):96.
   PubMedGoogle Scholar
• Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody Pembrolizumab in melanoma. J clin oncol. 2016;34(34):4102.
   PubMed Web of Science ®Google Scholar
• Hazarika M, Chuk MK, Theoret MR, et al. US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res. 2017;23(14):3484–3488.
   PubMed Web of Science ®Google Scholar
• Tang B, Chi Z, Chen Y, et al. Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial. Clin Cancer Res. 2020;26(16):4250–4259.
   PubMed Web of Science ®Google Scholar
• Si L, Zhang X, Shu Y, et al. A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151). Transl Oncol. 2019;12(6):828–835.
   PubMed Web of Science ®Google Scholar
• Li T, Jia -D-D, Teng L-S. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study. Invest New Drugs. 2020;38(5):1334–1341.
   PubMedGoogle Scholar
• Nathan P, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019;119:168–178.
   PubMed Web of Science ®Google Scholar
• Maeda T, Yoshino K, Nagai K, et al. Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients. Br J Dermatol. 2019;180(5):1230–1231.
   PubMedGoogle Scholar
• Nakamura Y, Namikawa K, Yoshino K, et al., Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol. 2020;31(9):1198–1206.
   PubMed Web of Science ®Google Scholar
• Warner AB, Palmer JS, Shoushtari AN, et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J clin oncol. 2020;38(15):1655.
   PubMedGoogle Scholar
• Cho J, Ahn S, Yoo KH, et al. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Invest New Drugs. 2016;34(6):677–684.
   PubMed Web of Science ®Google Scholar
• Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma. Cancer. 2016;122(21):3354–3362.
   PubMed Web of Science ®Google Scholar
• Ogata D, Haydu LE, Glitza IC, et al. The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med. 2021;10(7):2293–2299.
   PubMedGoogle Scholar
• Zhao L, Yang Y, Ma B, et al. Factors influencing the efficacy of anti-PD-1 therapy in Chinese Patients with advanced melanoma. J Oncol. 2019;2019:1–8.
   Google Scholar
• Tang B, Yan X, Sheng X, et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019;12(1):1–15.
   PubMedGoogle Scholar
• Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011;117(10):2202–2208.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 2011;305(22):2327–2334.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Lee S, Rubin KM, et al. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG‐ACRIN cancer research group (E2607). Cancer. 2017;123(14):2688–2697.
   PubMed Web of Science ®Google Scholar
• Carlisle BG, Zheng T, Kimmelman J. Imatinib and the long tail of targeted drug development. Nat Rev Clin Oncol. 2020;17(1):1–3.
   PubMedGoogle Scholar
• Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J clin oncol. 2011;29(21):2904–2909.
   PubMed Web of Science ®Google Scholar
• Kim K, Eton O, Davis D, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008;99(5):734–740.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Lawrence DP, Weber JS, et al. Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition. Clin Cancer Res. 2015;21(10):2289–2296.
   PubMed Web of Science ®Google Scholar
• Cho JH, Kim KM, Kwon M, et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs. 2012;30(5):2008–2014.
   PubMed Web of Science ®Google Scholar
• Delyon J, Chevret S, Jouary T, et al. STAT3 mediates nilotinib response in KIT-altered melanoma: a phase II multicenter trial of the French skin cancer network. J Invest Dermatol. 2018;138(1):58–67.
   PubMedGoogle Scholar
• Guo J, Carvajal R, Dummer R, et al. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017;28(6):1380–1387.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim TM, Kim YJ, et al., Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration: a multicenter trial of Korean cancer study group (UN10-06). Oncologist. 2015;20(11):1312.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Sosman JA, Lawrence DP, et al. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015;121(22):4007–4015.
   PubMed Web of Science ®Google Scholar
• Minor DR, Kashani-Sabet M, Garrido M, et al. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012;18(5):1457–1463.
   PubMed Web of Science ®Google Scholar
• Mao L, Si L, Chi Z, et al. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients. Eur J Cancer. 2011;47(10):1498–1503.
   PubMedGoogle Scholar
• Tarhini AA, Gogas H, Kirkwood JM. IFN-α in the treatment of melanoma. J Immunol. 2012;189(8):3789–3793.
   PubMed Web of Science ®Google Scholar
• Mao L, Dai J, Cao Y, et al. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021;148:297–306.
   PubMedGoogle Scholar
• Nakamura Y, Fujisawa Y. Diagnosis and management of acral lentiginous melanoma. Curr Treat Options Oncol. 2018;19(8):1–11.
   Google Scholar
• Schadendorf D, Fisher DE, Garbe C, et al. Melanoma. Nat Rev Dis Primers. 2015;1(1):1–20.
   Google Scholar
• Chen YA, Teer JK, Eroglu Z et al, . Translational pathology, genomics and the development of systemic therapies for acral melanoma. Semin Cancer Biol. 2020;61:149–157.
   PubMedGoogle Scholar
• Lee JT, Li L, Brafford PA, et al. PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas. Pigment Cell Melanoma Res. 2010;23(6):820–827.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob -J-J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J clin oncol. 2013;31(26):3205–3211.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714.
   PubMed Web of Science ®Google Scholar
• Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma,version 2.2019,NCCN clinical practice guidelines in oncology. J National Compr Cancer Network. 2019;17(4):367–402.
   PubMed Web of Science ®Google Scholar
• Ito T, Kaku-Ito Y, Murata M, et al. Immunohistochemical BRAF V600E expression and intratumor BRAF V600E heterogeneity in acral melanoma: implication in melanoma-specific survival. J Clin Med. 2020;9(3):690.
   Google Scholar
• Yeh I, Jorgenson E, Shen L, et al. Targeted genomic profiling of acral melanoma. JNCI. 2019;111(10):1068–1077.
   PubMedGoogle Scholar
• Bai X, Si L, Chi Z et al. Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma. J Clin Oncol. 2017;35(15): e21017–e21017.
   Google Scholar
• Yi JH, Yi SY, Lee HR, et al. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia. Melanoma Res. 2011;21(3):223–227.
   PubMed Web of Science ®Google Scholar
• Chang W, Lee SJ, Park S, et al. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma. Melanoma Res. 2013;23(2):147–151.
   PubMed Web of Science ®Google Scholar
• Maeda T, Hiura A, Uehara J, et al. Combined carboplatin and paclitaxel therapy improves overall survival in patients with nivolumab‐resistant acral and mucosal melanoma. Br J Dermatol. 2022;186(2):361–363.
   PubMedGoogle Scholar
• Hu T, Sun W, Xu Y, et al., Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China. Ann Transl Med. 2021;9(21): 1625–1625.
   PubMedGoogle Scholar
• Y-q G, Ding Y, D-d L, et al. Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma. Med Oncol. 2015;32(9):1–6.
   Google Scholar
• Namikawa K, Kiyohara Y, Takenouchi T, et al. Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma. J Dermatol. 2020;47(11):1257–1266.
   PubMedGoogle Scholar
• Takahashi A, Namikawa K, Ogata D, et al. Real‐world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. J Dermatol. 2020;47(11):1267–1275.
   PubMedGoogle Scholar
• Kato J, Hida T, Someya M, et al. Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma. J Dermatol. 2019;46(4):328–333.
   PubMed Web of Science ®Google Scholar
• Lee J, Chang JS, Roh MR, et al. Clinical outcomes of immune checkpoint blocker therapy for malignant melanoma in Korean patients: potential clinical implications for a combination strategy involving radiotherapy. Cancer Res Treat. 2020;52(3):730.
   PubMedGoogle Scholar
• Kim HK, Lee S, Kim K, et al., Efficacy of BRAF inhibitors in Asian metastatic melanoma patients: potential implications of genomic sequencing in BRAF-mutated melanoma. Transl Oncol. 2016;9(6):557–564.
   PubMedGoogle Scholar
• Fujisawa Y, Ito T, Kato H, et al. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: an analysis of 112 cases. Eur J Cancer. 2021;145:210–220.
   PubMedGoogle Scholar
• Mao L, Ding Y, Bai X, et al. Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Front Oncol. 2021;11:720044.
   PubMedGoogle Scholar
• Postow MA, Goldman DA, Shoushtari AN, et al. A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy J Clin Oncol. 2020;38:10003.
   Google Scholar
• Lebbe C, Meyer N, Mortier L, et al. Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: three-year results of CheckMate 511Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: three-year results of CheckMate 511. J Clin Oncol. 2021;39:9516.
   Google Scholar
• Mao L, Qi Z, Zhang L, et al. Immunotherapy in acral and mucosal melanoma: current status and future directions. Front Immunol. 2021;12:2088.
   Google Scholar